Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833431 | 0.87 | ALDH1A1 (0.58) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL10314578 | 0.81 | ALDH1A1 (0.53) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL30583271 | 0.80 | ALDH1A1 (0.67) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL5001108 | 0.80 | ALDH1A1 (0.67) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL11504542 | 0.80 | KDM4E (0.64) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL11504426 | 0.80 | KDM4E (0.64) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL10314577 | 0.78 | KDM4E (0.66) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL23450328 | 0.78 | HIF1A (0.61) | MAPTPOLBALDH1A1KDM4EGAA | |
| SCHEMBL9257129 | 0.78 | KMT2A (0.61) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL8358472 | 0.78 | HTT (0.52) | MAPTKMT2AMEN1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878853-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-1305026-B1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA SPA (IT) | 2009-05-13 | — | — | EP | disclosed |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | VIA ARIOSTO, 23 (IT) | 2008-05-15 | — | — | US | disclosed |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | VIA ARIOSTO, 23 (IT) | 2008-05-15 | — | — | US | disclosed |
| US-5942522-A | 1-BENZYL-3-ETHOXYCARBONYL-4-DIMETHYLAMINOETHOXY-6-METHYL-2-(1H) -QUINOLINONE; ANTIVIRAL AGAINST DNA CONTAINING VIRUSES, SUCH AS HERPES GROUP VIRUSES | SCHERING CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0549729-B1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORP (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5412104-A | Hypotensive and antiviral agents | SCHERING CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| US-5378694-A | Herpes viricide, hypotensive agent | SCHERING CORPORATION (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0550464-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1993-07-14 | — | — | EP | disclosed |
| EP-0549729-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0547145-A1 | ANTIVIRAL 2(1H)-QUINOLINONE COMPOUNDS | SCHERING CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992004328-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004326-A1 | ANTIVIRAL COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004327-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0354178-A1 | Thermoplastics containing a metal complex pigment | CIBA-GEIGY AG (CH) | 1990-02-07 | — | — | EP | disclosed |
| US-4866112-A | BISAZOLMETHINE WITH DIOXYQUINOLINYL RADICALS AS LIGAND | CIBA-GEIGY CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
| US-4153601-A | 4-Hydroxyquinolone-(2)-azomethine copper complex pigments | CIBA-GEIGY CORPORATION (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | MAPT 4789/4885KMT2A 453/4885MEN1 1922/4885 |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | MAPT 4727/4885KMT2A 386/4885MEN1 2094/4885 |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | HIF1A, HIF1AN, PDGFA | MAPT 3423/4885KMT2A 418/4885MEN1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.